The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 46 rounds in the feed, most often at Series A and in Biotech.
RA Capital founds, funds, and scales companies across healthcare and planetary health to build a healthier future for all.
Venture capitalracap.comRounds from 2021-01-07 to 2026-11-05
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Alethio Therapeutics A biopharmaceutical company developing therapies for myeloproliferative neoplasms (MPNs) | Series A Verified against 4 of 23 sources | $90M | 2026-11-05 | [ LEAD ] |
Optitvolt A startup developing a device to improve solar panel efficiency | Series A |
| $32M |
| ~ 2026-10-24 |
| [ PART ] |
STAR Therapeutics They develop and provide antibody therapies for patients with serious diseases. | Funding round Verified against 1 of 9 sources | $200M | 2026-10-22 | [ PART ] |
Optivolt A startup developing a device to improve solar panel efficiency | Series A Verified against 4 of 111 sources | $32M | 2026-10-21 | [ PART ] |
Circle Pharma A biopharmaceutical company advancing CID-165 for ER-positive breast cancer | Series E Verified against 5 sources | $92.5M | 2026-09-16 | [ PART ] |
Solstice Oncology Solstice Oncology develops immuno-oncology therapies aimed at treating early-stage cancers, specifically targeting colon cancer. | Series A Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $225M | 2026-09-09 | [ PART ] |
Typewriter Therapeutics A biotech developing re-dosable, all-RNA gene-insertion therapies, including in vivo CAR T, for cancer, autoimmune and severe genetic diseases | Series A Verified against 4 of 9 sources | $56M | 2026-09-02 | [ LEAD ] |
Abcuro Breakthrough therapies for autoimmune diseases and cancer for patients with specific conditions. | Series D Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $66M | 2026-08-18 | [ PART ] |
LifeMine LifeMine is a clinical-stage biopharmaceutical company that develops next-generation precision medicines through an innovative drug discovery approach focused on evolutionary insights from fungi, targeting patients in need of breakthrough therapies. | Series E Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $188M | 2026-08-06 | [ PART ] |
Celea Therapeutics Celeatx offers investigational medications, particularly deupirfenidone, for the treatment of idiopathic pulmonary fibrosis (IPF). | Funding round Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $180M | 2026-07-02 | [ PART ] |
Ollin Biosciences Ollin sells innovative therapies targeting serious eye diseases for patients. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $330M | 2026-06-24 | [ PART ] |
SonoThera SonoThera develops innovative ultrasound-mediated nonviral genetic therapies targeting various medical conditions. | Series B Verified against 1 of 4 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $125M | 2026-06-10 | [ PART ] |
CellCentric A drug-discovery platform | Series D Verified against 4 of 7 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $220M | 2026-05-06 | [ PART ] |
Windward Bio Windward Bio develops ultra-long-acting monoclonal antibodies for the treatment of serious respiratory and dermatologic diseases, targeting conditions like asthma and COPD. | Crossover financing Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $165M | 2026-05-04 | [ PART ] |
Terremoto Cutting-edge small-molecule therapies for cancer and other diseases targeted primarily at healthcare providers and researchers. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $108M | 2026-04-15 | [ PART ] |
Stipple Bio Stipple Bio develops targeted oncology therapies through precision mapping of tumor-specific epitopes for cancer treatment. | Series A Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2026-04-06 | [ LEAD ] |
Atavistik Bio Atavistik Bio develops novel allosteric therapeutics for serious diseases, particularly targeting proteins involved in conditions like Hereditary Hemorrhagic Telangiectasia (HHT). | Series B ext. Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $40M | 2026-03-05 | [ PART ] |
Slate Medicines Next-generation therapeutics for migraine and headache disorders targeting pathways involved in migraine pathophysiology. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $130M | 2026-02-24 | [ LEAD ] |
CORXEL Pharmaceuticals Innovative therapies for cardiometabolic diseases, targeting conditions such as obesity and Type 2 Diabetes Mellitus. | Series D+ Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $287M | 2026-01-22 | [ PART ] |
Kinaset Therapeutics Developing inhaled therapeutics for respiratory diseases, specifically targeting severe asthma patients. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $103M | 2026-01-10 | [ LEAD ] |
Diagonal Therapeutics They develop innovative clustering antibodies for the treatment of genetic diseases. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $125M | 2026-01-08 | [ PART ] |
Ambros Therapeutics Innovative medicines for diseases with high unmet medical need, specifically targeting Complex Regional Pain Syndrome Type 1. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $125M | 2025-12-16 | [ LEAD ] |
Triana Biomedicines Trianabio sells novel biopharmaceutical therapeutics focused on utilizing molecular glues to treat previously undruggable diseases, primarily targeting cancer. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $120M | 2025-12-03 | [ PART ] |
Artios Pharma Artios is a clinical-stage oncology company developing new medicines targeting DNA damage response pathways in cancer for patients with limited treatment options. | Series D Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $115M | 2025-11-17 | [ LEAD ] |
Hemab Therapeutics Hemab develops targeted therapies for bleeding disorders, focusing on conditions like Glanzmann Thrombasthenia and Von Willebrand Disease. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $157M | 2025-10-27 | [ PART ] |
ELECTRA Therapeutics Electra Therapeutics develops SIRP-directed therapies designed to improve outcomes for patients with immune-mediated diseases and cancer. | Series C Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $183M | 2025-10-22 | [ PART ] |
ADCytherix Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases such as cancer. | Series A Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $122.3M | 2025-10-16 | [ PART ] |
STAR Therapeutics They develop and provide antibody therapies for patients with serious diseases. | Series D Verified against 2 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $125M | 2025-09-30 | [ PART ] |
Reframe Systems Reframe Systems builds homes using AI, robotics, and automation, catering to developers and home buyers. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $20M | 2025-08-26 | [ PART ] |
Estuary Biotherapeutics A biotechnology company developing genetic medicines for patients with serious kidney diseases | Series A Verified against 1 of 14 sources | $93M | ~ 2025-05-30 | [ LEAD ] |
CellCentric A drug-discovery platform | Series C Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $120M | 2025-05-19 | [ LEAD ] |
Curevo Curevo Inc. develops an adjuvanted subunit vaccine for the prevention of shingles in adults. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $110M | 2025-03-17 | [ PART ] |
Abcuro Breakthrough therapies for autoimmune diseases and cancer for patients with specific conditions. | Series C Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $200M | 2025-02-12 | [ PART ] |
Verdiva Bio Verdiva Bio develops next-generation medicines aimed at treating obesity and cardiometabolic diseases. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $411M | 2025-01-09 | [ PART ] |
CellCentric A drug-discovery platform | Funding round Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $35M | 2024-07-24 | [ PART ] |
ADCytherix Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases such as cancer. | Seed Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $32.2M | 2024-06-11 | [ PART ] |
Diagonal Therapeutics They develop innovative clustering antibodies for the treatment of genetic diseases. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $128M | 2024-04-03 | [ PART ] |
MMI (Medical Microinstruments) A surgical-robotics company that makes the Symani system for microsurgery and super-microsurgery | Series C Developing, 4 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $110M | 2024-02-21 | [ PART ] |
Abcuro Breakthrough therapies for autoimmune diseases and cancer for patients with specific conditions. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $155M | 2023-08-17 | [ PART ] |
Hemab Therapeutics Hemab develops targeted therapies for bleeding disorders, focusing on conditions like Glanzmann Thrombasthenia and Von Willebrand Disease. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $135M | 2023-02-21 | [ PART ] |
Curevo Curevo Inc. develops an adjuvanted subunit vaccine for the prevention of shingles in adults. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $26M | 2022-11-16 | [ PART ] |
MMI (Medical Microinstruments) A surgical-robotics company that makes the Symani system for microsurgery and super-microsurgery | Series B Verified against 1 of 5 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $75M | 2022-07-20 | [ PART ] |
Triana Biomedicines Trianabio sells novel biopharmaceutical therapeutics focused on utilizing molecular glues to treat previously undruggable diseases, primarily targeting cancer. | Series A Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $110M | 2022-04-06 | [ LEAD ] |
ELECTRA Therapeutics Electra Therapeutics develops SIRP-directed therapies designed to improve outcomes for patients with immune-mediated diseases and cancer. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $84M | 2022-02-16 | [ PART ] |
Curevo Curevo Inc. develops an adjuvanted subunit vaccine for the prevention of shingles in adults. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $60M | 2022-02-10 | [ LEAD ] |
Abcuro Breakthrough therapies for autoimmune diseases and cancer for patients with specific conditions. | Series A Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $42M | 2021-01-07 | [ PART ] |